Minakem Header W48

Minakem Header W48

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Eligo Bioscience

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Eligo Bioscience Inks Deal with GSK Potentially Worth up to $224 Million

Details:

Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in acne.

Lead Product(s): EB005

Therapeutic Area: Dermatology Product Name: EB005

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: GSK

Deal Size: $224.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration January 11, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY